Observational studyFuture oncology (London, England)2026
Real-world data on patients with HR+, HER2- early breast cancer prescribed with abemaciclib adjuvant therapy for 2 years in Japan.
Observational study in Future oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to investigate patient characteristics and treatment patterns and completion rates over a 2-year follow-up period among Japanese patients with early breast cancer (EBC) who received adjuvant therapy with abemaciclib in real-world clinical practice.
methodsThis retrospective observational study used a Japanese administrative claims database to examine patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative EBC who received abemaciclib adjuvant therapy from December 2021-November 2024. Results were summarized descriptively.
resultsOf the 2042 eligible patients, 439 (median age [min-max] of 55 [26-84] years, with 99.3% being females) had a ≥2-year follow-up (median duration of follow-up: 890 days). Among these, 70.6% completed 2 years of abemaciclib+ endocrine therapy [ET], 21.9% discontinued abemaciclib but continued ET, and 7.5% discontinued both within 2 years. A dose of 300 mg/day was initiated in 92.3% of patients and dose reduction occurred in 58.3% of patients in 2-year follow-up group. Anti-diarrheal agents and probiotics were frequently prescribed initially, with rates declining over time.
conclusionsThis study demonstrates that adjuvant abemaciclib+ET is being used at the labeled dosage in most Japanese patients. Furthermore, 2-year completion rates in patients with 2-year follow-up were comparable to the clinical trial data from monarchE (69%).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.